Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal
NCT ID: NCT01713153
Last Updated: 2016-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1365 participants
INTERVENTIONAL
2012-06-30
2014-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Misoprostol and Oxytocin in UnijectTM for Postpartum Hemorrhage (PPH) Prevention in Mali
NCT01487278
Misoprostol for the Treatment of Postpartum Hemorrhage
NCT00116350
Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities
NCT01710566
Misoprostol for Preventing Postpartum Hemorrhage
NCT00124540
Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage
NCT01113229
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Misoprostol
600 mcg oral misoprostol administered during the third stage of labor
Misoprostol
600 mcg misoprostol oral
UnijectTM
10 IU oxytocin delivered IM with UnijectTM during he third stage of labor
UnijectTM
10 IU oxytocin delivered intramuscularly with UnijectTM
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Misoprostol
600 mcg misoprostol oral
UnijectTM
10 IU oxytocin delivered intramuscularly with UnijectTM
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ChildFund International
UNKNOWN
Gynuity Health Projects
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health huts in the district of Thiadiaye and Kolda
Thiadiay and Kolda, Thiadiaye and Kolda, Senegal
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Diop A, Daff B, Sow M, Blum J, Diagne M, Sloan NL, Winikoff B. Oxytocin via Uniject (a prefilled single-use injection) versus oral misoprostol for prevention of postpartum haemorrhage at the community level: a cluster-randomised controlled trial. Lancet Glob Health. 2016 Jan;4(1):e37-44. doi: 10.1016/S2214-109X(15)00219-3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2.4.9
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.